奥扎莫德治疗溃疡性结肠炎合并多发性硬化症患者：一石二鸟。
Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone.
作者信息
Vuyyuru Sudheer K, Morrow Sarah A, Jairath Vipul
机构信息
Department of Medicine, Division of Gastroenterology, Schulich School of Medicine, Western University, London, Ontario, Canada.
Department of Clinical Neurological Sciences, Schulich School of Medicine, Western University, London, Ontario, Canada.
出版信息
ACG Case Rep J. 2023 Jan 20;10(1):e00955. doi: 10.14309/crj.0000000000000955. eCollection 2023 Jan.
Simultaneous occurrence of multiple sclerosis (MS) and ulcerative colitis (UC) is seldom encountered by clinicians and poses unique challenges. The sphingosine-1-phosphate receptor modulator ozanimod has been recently approved for UC. Ozanimod can be used in such scenarios where it can treat both conditions, reducing the need for multiple targeted therapies. We report the first case of successfully treated multiple sclerosis and UC with ozanimod.
临床医生很少遇到多发性硬化症（MS）和溃疡性结肠炎（UC）同时发生的情况，这带来了独特的挑战。鞘氨醇-1-磷酸受体调节剂奥扎莫德最近已被批准用于治疗UC。奥扎莫德可用于能同时治疗这两种病症的情况，减少了对多种靶向治疗的需求。我们报告了首例使用奥扎莫德成功治疗多发性硬化症和UC的病例。
Zotero 插件